Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

ARMO BioSciences, Inc. - Common Stock (NQ: ARMO )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about ARMO BioSciences, Inc. - Common Stock

Asceneuron Appoints Peter Van Vlasselaer as Chairman
From PR Newswire
Lilly Completes Acquisition of ARMO BioSciences
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). 
From PR Newswire
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance. Six New Biotechnology Companies Added to the Index. 
From Business Wire News Releases
Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc.,
From PR Newswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of ARMO BioSciences, Inc. Buyout
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of ARMO BioSciences, Inc. Buyout 
From Business Wire News Releases
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of ARMO BioSciences, Inc. - ARMO
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating ARMO BioSciences,... 
From PR Newswire
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
From ACCESSWIRE
Biotech Sector Volatile Ahead of Trump Announcement
From PR Newswire
NASDAQ:ARMO Investor Alert: Investigation over Possible Wrongdoing in Acquisition of ARMO BioSciences, Inc
San Diego, CA -- (SBWIRE) -- 05/14/2018 -- An investigation was announced for investors, who currently hold shares of ARMO BioSciences, Inc. (NASDAQ: ARMO),over the takeover of ARMO BioSciences, Inc.... 
From SBWire - Latest Press Releases
WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ARMO BioSciences Inc. ("ARMO" or the "Company") (NASDAQ: ARMO) in connection... 
From PR Newswire
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
From ACCESSWIRE
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of ARMO BioSciences, Inc. (ARMO) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, is Investigating the Sale of ARMO BioSciences (ARMO) on Behalf of Stockholders and Encourages Investors to Contact the Firm 
From Business Wire News Releases
ARMO BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
ARMO BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout 
From Business Wire News Releases
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc.
Rowley Law PLLC is investigating potential claims against ARMO BioSciences, Inc. (NASDAQ: ARMO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the... 
From PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of ARMO BioSciences, Inc. to Eli Lilly is Fair to Shareholders
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of ARMO BioSciences, Inc. 
From Business Wire News Releases
ARMO BioSciences Alert: Johnson Fistel Investigates Proposed Sale of ARMO BioSciences, Inc.; Is $50 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ARMO BioSciences, Inc. (NASDAQ: ARMO) breached their fiduciary duties in connection with... 
From PR Newswire
Lilly Announces Agreement To Acquire ARMO BioSciences
$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types 
From PR Newswire
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a long-acting PEGylated form of recombinant human Interleukin-10... 
From GlobeNewswire News Releases
New Research: Key Drivers of Growth for Maiden, Oaktree Capital Group, Broa, ARMO Biosciences, Hillenbrand, and Equity Commonwealth — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Maiden Holdings, Ltd.... 
From GlobeNewswire News Releases
ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder, will participate in a... 
From GlobeNewswire News Releases
ARMO BioSciences Reports FY 2017 Financial Results
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced its financial results for the fiscal year ended December 31, 2017. 
From GlobeNewswire News Releases
ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced enrollment of its first patient in CYPRESS 2, a randomized Phase 2b trial designed to investigate... 
From GlobeNewswire News Releases
ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced the completion of the first interim analysis in its Phase 3 SEQUOIA study in patients with pancreatic cancer.... 
From GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Amicus Therapeutics, Ampio Pharmaceuticals, AmpliPhi Biosciences, and ARMO BioSciences
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on FOLD, AMPE, APHB, and ARMO which can be accessed for free by signing up to... 
From PR Newswire
ARMO BioSciences, Inc. (Nasdaq: ARMO) to Ring The Nasdaq Stock Market Closing Bell
From GlobeNewswire News Releases
ARMO BioSciences Announces Pricing of Initial Public Offering
ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of... 
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.